TY - JOUR
T1 - Computational Advancement towards the Identification of Natural Inhibitors for Dengue Virus
T2 - A Brief Review
AU - Arslan Sehgal, Sheikh
AU - Tur Razia, Iashia
AU - Kanwal, Ayesha
AU - Ahsan, Muhammad
AU - Adnan Tahir, Rana
AU - Sajid, Muhammad
AU - Saleem Khan, Muhammad
AU - Mukhtar, Naila
AU - Parveen, Gulnaz
AU - Sajid, Muhammad
N1 - Copyright© Bentham Science Publishers; For any queries, please email at epub@benthamscience.net.
PY - 2023/10/6
Y1 - 2023/10/6
N2 - Viral infectious illnesses represent a severe hazard to human health due to their widespread incidence worldwide. Among these ailments, the dengue virus (DENV) infection stands out. World Health Organization (WHO) estimates that DENV infection affects ~400 million people each year, with potentially fatal symptoms showing up in 1% of the cases. In several instances, academic and pharmaceutical researchers have conducted several pilot and clinical studies on a variety of topics, including viral epidemiology, structure and function analyses, infection source and route, therapeutic targets, vaccinations, and therapeutic drugs. Amongst Takeda, TAK-003, Sanofi, Dengvaxia®, and Butantan/NIH/Merck, Dengvaxia® (CYD-TDV) is the only licensed vaccination yet; however, the potential inhibitors are under development. The biology and evolution of DENVs are briefly discussed in this review, which also compiles the most recent studies on prospective antiviral targets and antiviral candidates. In conclusion, the triumphs and failures have influenced the development of anti-DENV medications, and the findings in this review article will stimulate more investigation.
AB - Viral infectious illnesses represent a severe hazard to human health due to their widespread incidence worldwide. Among these ailments, the dengue virus (DENV) infection stands out. World Health Organization (WHO) estimates that DENV infection affects ~400 million people each year, with potentially fatal symptoms showing up in 1% of the cases. In several instances, academic and pharmaceutical researchers have conducted several pilot and clinical studies on a variety of topics, including viral epidemiology, structure and function analyses, infection source and route, therapeutic targets, vaccinations, and therapeutic drugs. Amongst Takeda, TAK-003, Sanofi, Dengvaxia®, and Butantan/NIH/Merck, Dengvaxia® (CYD-TDV) is the only licensed vaccination yet; however, the potential inhibitors are under development. The biology and evolution of DENVs are briefly discussed in this review, which also compiles the most recent studies on prospective antiviral targets and antiviral candidates. In conclusion, the triumphs and failures have influenced the development of anti-DENV medications, and the findings in this review article will stimulate more investigation.
UR - https://www.mendeley.com/catalogue/aa7f5e0f-d58f-3afa-8cc0-4bbc6c3f2053/
U2 - 10.2174/0113862073244468230921050703
DO - 10.2174/0113862073244468230921050703
M3 - Article
C2 - 37859315
SN - 1386-2073
VL - 26
JO - Combinatorial Chemistry and High Throughput Screening
JF - Combinatorial Chemistry and High Throughput Screening
ER -
